Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 83

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 83
---
 process, the Compensation Committee typically recommends, and the Board approves, the grant of equity, which historically has taken the form of stock options and RSUs, to executive employees, which are ultimately granted on the first business day of the following fiscal year. Lining up the timing of equity grants to coincide with grants made to the Board under the Company’s Non-Employee Director Compensation Program serves to ensure that management and the Board have a stake in the Company’s success and growth. We also believe this allows management, the Compensation Committee, and the Board to conduct a fulsome review of all elements of compensation on a consistent basis each year. The Board, with respect to our CEO, and the

<div align='center'>48</div>

Compensation Committee, with respect to our remaining Named Executive Officers, may also grant equity awards from time to time in recognition of a named executive officer’s expanded duties and responsibilities or continuing contributions to the Company’s performance.

Neither the Compensation Committee nor the Board takes material nonpublic information into account when determining the timing and terms of grants of equity compensation. Further, we do not have any program, plan or practice to time grant dates of equity compensation awards in coordination with the release of material nonpublic information and have not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.

Pursuant to Item 402(x) of Regulation S-K under the Exchange Act, we are providing the following information regarding awards granted to named executive officers of the Company on January 2, 2024, which was four business days before the filing of a Current Report on Form 8-K with which the Company furnished a then-current version of its corporate presentation.

| Named Executive Officer     |     | Grant date |     |          |     | Number of Shares |         |     | Per share exercise price of the award |        |     | Grant date fair value of the award |           |     | Percentage change in the closing market price of the securities underlying the award between the trading day immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information |   |   |
|:----------------------------|:----|:-----------|:----|:---------|:----|:-----------------|--------:|:----|:--------------------------------------|-------:|:----|:-----------------------------------|----------:|:----|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--:|:--|
| Carsten Brunn, Ph.D.        |     |